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Key Points  
 
1. A new Gata2 reporter indicates that all HSCs express Gata2 and corroborates findings 
that Gata2 is not required for generation of all HPC.  
2. Isolatable Gata2-non-expressing HPCs show less potency and a distinct genetic program, 
thus having implications for reprogramming strategies.   
 
 
Abstract 
The Gata2 transcription factor is a pivotal regulator of hematopoietic cell development and 
maintenance, highlighted by the fact that Gata2 haploinsufficiency has been identified as the 
cause of some familial cases of AML/MDS and in MonoMac syndrome. Genetic deletion in 
mice has shown that Gata2 is pivotal to the embryonic generation of hematopoietic stem 
cells (HSC) and hematopoietic progenitor cells (HPC). It functions in the embryo during 
endothelial cell to hematopoietic cell transition (EHT) to affect hematopoietic cluster, HPC 
and HSC formation. Gata2 conditional deletion and overexpression studies show the 
importance of Gata2 levels in hematopoiesis, during all developmental stages. Although 
previous studies of cell populations phenotypically enriched in HPCs and HSCs show 
expression of Gata2, there has been no direct study of Gata2 expressing cells during normal 
hematopoiesis. In this study we generate a Gata2Venus reporter mouse model with 
unperturbed Gata2 expression to examine the hematopoietic function and transcriptome of 
Gata2 expressing and non-expressing cells. We show that all the HSCs are Gata2 
expressing. However, not all HPCs in the aorta, vitelline and umbilical arteries and fetal liver 
require or express Gata2. These Gata2-independent HPCs exhibit a different functional 
output and genetic program, including Ras and CREB pathways and other Gata factors, 
when compared to Gata2-dependent HPCs. Our results, indicating that Gata2 is of major 
importance in programming towards HSC fate but not in all cells with HPC fate, have 
implications for current reprogramming strategies.   
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Introduction 
Gata2 is one of the ‘heptad’ transcription factors that acts on regulatory regions of 
hematopoietic genes1. It is upregulated in vivo in Ly6aGFP+ cells undergoing endothelial-to-
hematopoietic cell transition (EHT), a process by which definitive hematopoietic progenitors 
(HPC) and HSCs are generated in the embryo2,3. As one of the major regulators of HPC and 
HSC generation, germline deficiency of Gata2 results in embryonic lethality between E10-
E10.5 and an anemic phenotype, with a decreased number of primitive and definitive HPCs 
in the yolk sac (YS) and in Gata2-/- ES cell hematopoietic differentiation cultures4-6. Chimeric 
embryo generation with Gata2-/- ES cells revealed defective production of all hematopoietic 
lineages5. The E10.5 lethality of Gata2-/- embryos precludes the study of HSC generation in 
the aorta-gonad-mesonephros (AGM) region, the first site of de novo HSC production. 
Gata2+/- embryos contain greatly reduced number of HSCs in the AGM region7,8. Gata2 
haploinsufficiency perturbs adult HSC homeostasis in mouse9, and in man leads to MonoMac 
syndrome10, which is associated with sporadic myelodysplasia and myeloid leukemia. Also, 
rearrangement of the remote Gata2 enhancer drives acute myeloid leukemogenesis by 
activating Evi1 expression11,12. Overexpression studies also reveal that levels of Gata2 
expression are important for its hematopoietic function13-15. In situ hybridization studies 
localize Gata2 expression to aortic endothelial cells, intraaortic hematopoietic cluster cells, 
placenta (PL) and fetal liver (FL) in the midgestation mouse16-18. Conditional knockout of 
Gata2 or Gata2 regulatory elements in vascular endothelial cells indicates that Gata2 is 
essential for hematopoietic cluster formation and HSC generation7,19,20. Gata2 plays a role in 
the emergence of cKit-expressing hematopoietic cells from the endothelium7. Later, as 
shown in VavCre conditional knockout mice, Gata2 is essential for HSC maintenance7, thus 
demonstrating a role for Gata2 as previously recognized in bone marrow LSK HSCs21. 
To date, the correlation between Gata2 and hematopoietic cell generation in the 
embryo has been made in the absence of prospective isolation of viable Gata2-expressing 
cells16. Although some hematopoietic cells remain in the embryo in the absence of Gata25-8, 
the identity of these cells is unknown. In this study, to further understand the requirement for 
Gata2 in normal hematopoietic development, we create and use a mouse model in which a 
fluorescent reporter for Gata2 (IRES-Venus knock-in gene) does not affect the normal level 
or function of Gata2. We demonstrate that all long-term repopulating HSCs and a large 
percentage of HPCs in the midgestation mouse embryo are Venus-positive. We isolate and 
characterize a Venus-negative HPC population that corresponds to the HPCs found in 
Gata2-null embryos. Gata2-independent hematopoietic progenitors are functionally less 
complex and do not follow the same genetic program as Gata2-dependent HPCs.  
 
Materials and methods 
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Gata2Venus ESC and mice. Generation of the Gata2-Venus mouse model is described in 
the online supplementary methods. In short, an IRES-Venus fragment and a loxP-PGK-Puro-
loxP fragment were inserted in the Gata2 3’UTR. IB10 ESCs were transfected, puromycin-
selected and 360 clones PCR screened for Gata2Venus (right arm junction 2292bp). Correct 
integration was verified by Southern blot (left arm) for 2 clones with normal karyotype. 
Founders were identified by Venus PCR. First generation G2V offspring were crossed with 
CAG-Cre mice22 and backcrossed (>10 generations) with C57BL/6. 
 
Mice and embryo production. Gata2+/- mice5, Ly5.1(6-8 week) and C57BL/6 mice were 
obtained/maintained (Harlan or locally) and genotyped by PCR (online supplementary 
methods). Day of plug discovery is embryonic day (E)0. Embryos were staged by somite pair 
(sp): E9.5=16-28sp, E10=28-40sp, early E10=28-34sp, E10.5=35-40sp, E11=40-50sp. 
 
Immunostaining. Whole-mount conceptuses were stained and imaged23; cryosections and 
flowcytometry were stained8 using anti-CD34-biotin (1:50, BD), anti-Gata3 (1:10 KT122, 
111207H09, Absea) and anti-Gata4 (1:50 H-112, sc-9053, SantaCruz) and anti-GFP 
antibodies. For flow cytometry8, cells were stained with anti-CD31(390, BD), anti-
CD34(RAM34, BD), anti-cKit(2B8, BD), anti-CD41(MWReg3, SantaCruz), anti-Sca1(D7, 
Ebiosciences) and anti-CD16/32(2.4G2, BD) antibodies, Hoechst 33258 (BD) and analysed 
(FACSARIAIII/SORP).  
 
Hematopoietic assays. Venus-sorted E9-E11AGM, VA+UA, PL and YS and E10FL or Gata2-
deficient E9-E10 AGM, VA+UA and PL were seeded in 3.6ml Methylcellulose (1ml per dish; 
M3434, StemCellTech) for 10-12 days24. Colonies were counted, isolated, washed and 
Venus expression examined (FACSARIAIII/Fortessa). Sorted G2V E11AGM (Ly5.1/Ly5.2) 
cells were transplanted24 into 9.5Gy-irradiated (C57BL/6 x 129)F1 recipients (Ly5.2/Ly5.2) 
together with 2x105 spleen cells from the recipient strain. Peripheral blood (PB) donor 
chimerism was determined by Venus PCR and/or FACS at 4mo post-transplantation and 
scored positive if PB donor chimerism was >10%. 
 
RNA analyses. Detailed RNA procedures are provided in Online Supplemental Methods. 
GEO Data Accession Number is GSE76254. Briefly, RNA was isolated from E10.5 AGM 
CD31 and cKit sorted cells with mirVana miRNA Kit (Ambion) and quality/quantity assessed 
by 2100Bioanalyzer (Agilent; RNA Nano/Pico chip). RNAsequencing used SMARTER 
protocol for Illumina HiSeq2000 and analysed25,26,27. For qRT-PCR, SuperScriptII/III 
ReverseTranscriptase (LifeTechnologies) was used for first-strand cDNA synthesis. Primers 
are specified in Suppl Table1. β-actin=normalization control. 
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Results 
Generation and validation of a novel Gata2 reporter mouse model 
Previously, analysis of Gata2-expressing cells has been limited to a reporter mouse 
model that results in Gata2 haploinsufficiency16. Our approach allows for the expression of 
the reporter within the Gata2 genomic locus without affecting the levels of Gata2 expression 
or protein function. This is particularly important since Gata2 haploinsufficiency greatly 
reduces the number of HS/PCs generated during development7,8,19,20,28. Briefly, an internal 
ribosome entry site sequence (IRES) followed by the Venus fluorochrome gene was 
recombined into the Gata2 3’UTR (Fig1A) in embryonic stem cells (ESC). The resulting 
Gata2Venus (G2V) mice bred normally and showed no overt growth or hematopoietic 
defects.  
To determine whether Venus reporter expression parallels that of Gata2, G2V bone 
marrow (BM) cells were sorted into Venus-expressing (Venus+) and non-expressing (Venus-) 
fractions (Fig1B). qRT-PCR for Gata2 and Venus transcripts (Gata2V/+ BM) demonstrated 
that only Venus+ cells express Venus and Gata2 mRNA (Fig1C). Western blot analysis 
revealed that equivalent amounts of Gata2 protein were present in Gata2+/+ and Gata2V/V 
adult BM cells (data not shown). FACS analysis showed that Gata2v/v BM LSK cell numbers 
(388/105) are comparable to WT BM LSK numbers (378/105). Importantly, the results of 
competitive limiting dilution transplantation analyses of Gata2V/V and WT BM cells 
demonstrate that HSCs are qualitatively and quantitatively normal in this mouse model 
(Fig1D). Thus, Venus expression correctly reports Gata2 expression without interfering with 
its normal expression levels or function.  
 
Gata2 is expressed in emerging aortic hematopoietic cluster cells and other 
embryonic hematopoietic tissues 
Venus expression was examined in midgestation G2V hematopoietic tissues. Flow 
cytometry revealed that E9-E11 AGM, yolk sac (YS), PL and FL contained Venus+ cells 
(Fig1E). At E9, 6.28%±0.47 of viable YS cells and 1.82%±0.31 of AGM cells are Venus+. At 
E10.5 (when the first HSCs are generated) 3.27%±0.52 of AGM cells are Venus+ and this 
increases to 19.27%±2.14 at E11. Table1 shows the frequencies of Gata2-expressing cells. 
Whole mount images of E10 and E11 G2V embryos immunostained with anti-CD31 
antibody (marks all endothelial cells and hematopoietic cluster cells) shows Venus+ cells 
along the aorta (DA). Venus+ cells are also observed in cells of the neural tube (NT), 
olfactory bulb (OB) and FL (Fig2A-C). In the E10.5 AGM region (DAPI- and CD31-stained 
(blue and red respectively)), Venus expression is found in endothelial and hematopoietic 
cluster cells mainly on the ventral side of the DA and in the urogenital (UG) region (Fig2D,E). 
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In the FL, Venus-expressing cells are found in a punctate distribution pattern (Fig2D,F). At 
E9, Venus is expressed in the some of the CD34+ (red) endothelial cells of the paired aorta 
(Fig2G, arrowhead) and also in some of the endothelial and hematopoietic cluster cells of the 
umbilical artery (UA) (Fig2H). Venus continues to be expressed at E11 in some aortic 
endothelial cells, and emerging/other hematopoietic cluster cells (Fig2I, arrowhead). The 
E10.5 YS shows Venus expression in some of the CD31+ (red) endothelial cells. Overall, 
Venus expression is similar to what has been previously documented for Gata2 in situ 
hybridization analysis29,30. Thus, our model allows for the prospective identification, isolation 
and characterization of Gata2-expressing cells during normal development.  
  
All HSCs, but not all HPCs, express Gata2  
To test for HSC activity, E11 AGM Venus+ and Venus- cells were transplanted into 
irradiated adult recipients. All long-term repopulating HSCs were found in the Gata2Venus-
expressing fraction (Fig3A). 9 of 19 recipients receiving Venus+ cells were engrafted (15-
71%), whereas none of 14 Venus- recipients showed donor-derived hematopoietic cells. 
These HSCs were multilineage-repopulating (Supplemental Fig1) and self-renewing (8 
repopulated of 12 transplanted with 3x106 BM cells from primary repopulated mice, n=4).  
The relationship between Gata2 expression and HPC function was also examined. E9 
and E10 AGM Venus+ and Venus- cells were plated in the CFU-C assay. High enrichment of 
HPCs was found in the Venus+ fractions (Table2). Surprisingly, HPCs were found also in the 
Venus- fraction, although there were very few. At E9 the Venus+ and Venus- fractions 
respectively yielded 8.0±2.1 and 0.4±0.4 CFU-C per AGM. CFU-C numbers increased in the 
Venus+ cell fraction at E10 (69.0±7.1), and the Venus- fraction increased to 8.0±2.3 CFU per 
AGM. However, bi- and multi-potent progenitors were found only in the Venus+ fraction 
(Fig3B).  
HPC activity was also examined in the Venus+ and Venus- fractions of other 
hematopoietic tissues (Table2). E9 and E10 vitelline+umbilical arteries (VA+UA; Fig3C), YS 
(Fig3D) and PL (Fig3E), and E10 FL (Fig3F) contained progenitors in both fractions. Most 
HPCs were Venus+. The greatest number of CFU-C arising from Venus- cells was found in 
the E9 YS (270.0±69.8 CFU-C/YS). These data indicate that some HPCs are not expressing 
Gata2. BFU-E, CFU-G and CFU-M were the predominant colony types in both fractions, and 
in contrast to the Venus+ fractions, the Venus- fractions of VA+UA, YS, FL and PL yielded few 
or no CFU-GEMM. Thus, all AGM HSCs express Gata2, Gata2 expression is associated with 
immature HPCs, but not all HPCs are Gata2-expressing. 
 
Some HPCs and vascular cluster cells are formed in the absence of Gata2 
Since the Venus- fractions of midgestation G2V hematopoietic tissues contain CFU-C, 
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we tested whether such hematopoietic progenitors are present in Gata2-deleted embryos. 
CFU-Cs were detected in the Gata2-/- E9 AGM, E10 AGM (Fig4A) and E10 VA+UA (Fig4B), 
although significantly fewer as compared to WT (Table3). Gata2+/- tissues also contained 
fewer CFU-Cs compared to WT. The E9 Gata2-/- YS contained the most CFU-C 
(64.4±12.2)(Fig4C). In VEC-Cre:Gataf/f embryos, E10 PL showed significantly decreased 
CFU-C numbers (Fig4D), as did E10 AGM and YS7 when compared to WT. The CFU-C 
remaining in Gata2-/- embryos are predominantly CFU-G and CFU-M. Very few Gata2-/- CFU-
GM and no CFU-GEMM were observed. These data support and validate our findings in G2V 
embryos that not all HPCs are Gata2-expressing, Gata2-independent progenitors exist in 
each of the early hematopoietic tissues, and the Gata2-expressing cell fraction is more 
enriched in multipotent progenitors. 
Since hematopoietic clusters appear in the VA and UA prior to appearance in the 
aorta, and are larger than in the AGM31, we further examined these vessels. Whole-mount 
microscopic analysis demonstrates that clusters form in the absence of Gata2. The number 
and size of cKit+ hematopoietic clusters in early E10 Gata2+/- and Gata2-/- VA+UA are 
decreased as compared to WT(Fig4E). The number of cKit+ cells decreases 20-fold in the 
E10 Gata2-/- VA+UA (Fig4F) in correspondence to the decrease in VA+UA CFU-C (Fig4B), 
suggesting that these emerging cKit+ hematopoietic cluster cells are part of the cohort of 
Gata2-independent HPCs.  
 
An alternative genetic program is expressed in Venus- hematopoietic cells  
The molecular basis for the functional differences observed in Gata2-dependent and -
independent HPCs was examined by RNAsequencing. As most CD31+Venus- HPCs showed 
ckit intermediate (int) expression, we compared this population to CD31+Venus+ckitint HPCs 
(Fig5A). Gene set enrichment analysis (GSEA) on genes sorted by log ratio of Venus+ versus 
Venus- FPKMs revealed that genes in the Ras signalling pathway were significantly enriched 
in the Venus+ as compared to the Venus- fraction (Fig5B). Genes upregulated by Ras were 
enriched in the Venus+ fraction, and highly upregulated genes included Kras, Grb2 (Ras 
adaptor), and Sos1 and Sos2 (RasGEF activators) (Fig5C). Genes downregulated by Ras 
were enriched in the Venus- fraction. RasGAP gene (render Ras inactive) Rasa2 was highly-
upregulated in the Venus- fraction, whereas Rasa1 and Rasa3 were highly-upregulated in the 
Venus+ fraction. Rasa4 and NF1 were expressed to similar levels. Also, Venus+ HPCs show 
increased levels of CREB and CBP expression as compared to Venus- HPCs, and express 
PKA catalytic subunit genes, suggesting that Venus+ HPCs have the potential to activate 
CREB target genes. Gata2 has CREB Response Element consensus sites (-3kb,-300bp 
upstream tss) suggesting that it is a downstream target32,33. As Gata2 is a Notch target18, a 2-
4-fold higher expression of Notch1 and Notch4 was found in the Venus+ fraction (Fig5D). 
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Moreover, Snw1 and Maml1 (transcriptional co-activators in the Notch pathway that interact 
with Notch) were upregulated (2- and 30-fold respectively) in Gata2-expressing HPCs.  
Since Venus- HPCs are mainly restricted in their differentiation potential to the 
macrophage and granulocytic lineages, we evaluated their similarity to YS-derived 
erythromyeloid progenitors (EMPs) that give rise to tissue-resident macrophages. Flow 
cytometric analysis for EMP markers34 showed that 3.89% of E10 YS and 0.72% of E10 
AGM cells were EMPs (Sca1-ckit+CD41+CD16/32+). The majority of EMPs were Venus- (74% 
in YS, 85% in AGM) (Fig5F). At E11, the frequency of EMPs in the E11 YS and AGM 
decreased to 2.11% and 0.11% respectively (Fig5F), with 60% of YS and 77% of AGM EMPs 
now being Venus+. Published transcriptome data on mouse YS EMPs show the low 
expression of several chemokine receptors/ligands (Cx3cr1, Cx3cl1, Ccl2, Ccr1, Ccl9 and 
Ccr7)35. The expression of these genes was low or absent in Venus- AGM cells as compared 
to Venus+ cells (Fig5F). Also, Cxcr4 (highly-expressed in EMPs) was highly-expressed in 
Venus- AGM cells as compared to Venus+ cells. These results suggest that the Venus- 
population shares similarities to EMPs at the transcription level. 
Analysis of FPKMs for heptad transcription factors previously described as expressed 
in AGM HSCs and HPCs1-3 showed expression in both the Venus+ and Venus- AGM fractions 
(data not shown). Also, other Gata factors were expressed in both fractions. In the mouse 
Gata1, 2 and 3 are hematopoietic transcription factors, whereas the Gata4, 5 and 6 factors 
are not directly related to hematopoiesis. qRT-PCR performed on E10.5 AGM CD31+cKit+ 
cells (Fig6A) confirmed Gata3 expression by both the Venus+ and Venus- fractions, and 
Gata4 was significantly higher in the Venus- fraction. Gata1, 5, 6 transcripts were low/not 
detected. Immunostaining of E10.5 AGM (WT) showed Gata3-expressing cells in the 
mesenchyme underlying the ventral aspect of the aorta, aortic endothelial cells and some 
cells emerging from the aortic wall (Fig6B) in agreement with Fitch36. G2V E10.5 AGM 
confirmed that some aortic endothelial cells co-express Gata3 and Gata2(Fig6C). Gata4 
expression was also found in aortic endothelial (CD34+) cells, but it did not overlap with 
Gata2 expression(Fig6D). Together, these results suggest that Gata3 and/or Gata4 may 
provide some function in Gata2-independent hematopoietic cells.  
 
Discussion 
In this study we prospectively enriched and characterized Gata2-dependent and –
independent HPC subsets from our novel Gata2Venus reporter mouse. Molecular analyses, 
together with the fact that some vascular hematopoietic cluster cells and HPCs persist in the 
absence of Gata2 expression suggest that an alternative genetic program exists for the 
production of HPCs. The transcriptome differences observed between Venus+ and Venus- 
HPCs may offer possibilities for pathway modifications to achieve the programming 
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complexities necessary for the generation/function of normal definitive HPCs and provide 
insights into the factors involved in myeloid leukemogenesis.     
 
Gata2 expression in the developing hematopoietic system 
We showed the temporal and quantitatively coordinate transcription of Venus and 
Gata2 in our G2V mouse model. The strategy used37 eliminates expression level and protein 
alterations that affect HP/SC development. In G2V embryos, we showed that the cells with 
the most robust and complex hematopoietic potential (all HSCs and most HPCs) are Gata2-
expressing. Imaging and FACS analyses of G2V embryos confirm that Gata2 is expressed in 
all hematopoietic sites during midgestation and that the numbers of Gata2-expressing cells 
reflect the developmental and temporal hematopoietic changes occurring in each site. At E9 
Gata2-expressing cells are found predominantly in the YS, which at this time produces the 
highest numbers of the hematopoietic progenitors (EMP) in the conceptus. Slightly later as 
hematopoiesis begins in the AGM and FL, the numbers of Gata2-expressing cells also 
increase. The highest numbers of CD31+cKit+ cluster cells are found in the aorta, VA and UA 
at E10.5, as quantitated by whole mount embryo imaging31. Most, but not all hematopoietic 
cluster cells express Gata2, and Gata2 expression may be downregulated as HPCs 
differentiate. However, we found some hematopoietic cluster cells and HPCs in the E10 
Gata2-/- vasculature, confirming the existence of Gata2-independent HPCs5.  
 Importantly, Gata2 is expressed in the endothelial cells of the DA. Already at E8.5, 
endothelial cells lining the paired dorsal aortae express Gata2 and it continues to be 
expressed in the E10.5 aorta when HSCs are generated, thus highlighting an involvement of 
Gata2 in the hemogenic program of endothelial cells. Data in VE-cadherin conditional Gata2-
deficient mice and other models7,19,28,38 strongly support the notion that Gata2 is required in 
hemogenic endothelium for the emergence of HSCs, as does the morpholino knockdown of 
Gata2b in Zebrafish39.  
 
Gata2 and the relationship with hematopoietic function 
Prospective isolation and in vivo transplantation showed that all HSCs are Gata2-
expressing. In contrast, some HPCs are present in the Venus- cell fractions of G2V 
hematopoietic tissues and Gata2-/- hematopoietic tissues. In both cases, the HPCs are 
restricted in their differentiation potential to predominantly the macrophage and granulocytic 
lineages. Currently, the EMP population is of high interest as a novel hematopoietic cell 
subset providing tissue resident macrophages35,40-42. Our FACS data revealed that EMPs are 
mainly in the Venus- cell population of E10 YS and AGM, and increased in the Venus+ 
population at E11. Chemokine receptor/ligand gene sets obtained from a study on 
EMP/microglia transcriptome comparisons allowed us to find similarities in chemokine 
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receptor/ligand expression between EMPs and the Venus- HPC fraction.  
Despite prevalence of EMPs in the Venus- cell population in E10 YS and AGM, 
definitive progenitors are largely Venus+. The co-existence of these HPC subsets highlight 
the fact that there is more diversity in the types of progenitors generated in the embryo than 
was previously appreciated. In support of this is recent data from ESC hematopoietic 
differentiation cultures suggesting that there are two different hemogenic endothelial cell 
subsets43 and the fact that in vivo, the AGM, VA/UA, YS, PL and head are all hemogenic 
tissues 34,44,45,46,47.  
The highest number of Venus- HPCs were found in E9 and E10 YS (270.0±69.8 and 
130.0±25.5 CFU-C, respectively) as compared to other tissues (PL, AGM, VA+UA). It is clear 
that Gata2 has an important role in EHT in the hemogenic endothelial cell compartment 
before or during the generation/emergence of hematopoietic cells, as evidenced by the 
decrease (but not absence) in the hematopoietic cluster cells in Gata2-/- aorta, VA and UA. 
However, it is as yet unclear at what frequency EHT occurs in the YS, thus raising the 
possibility that Gata2-independent HPCs arise differently than Gata2-dependent HPCs 
(perhaps directly from hemangioblasts48).  
We found differences in the number of CFU from E9 YS Venus- cells (270.0±69) and 
Gata2-/- cells (64.4±12.2) (Fig4C,3D, Tables 2,3). The 4-fold lower CFU number is likely 
related to observations (ours and others) that colonies from Gata2-/- embryos, YS explants 
and ESC differentiations were smaller/less proliferative than WT colonies, due to the 
complete absence of Gata26,7. Venus- cells are not defective for Gata2 and resulting colonies 
are normal in size. Whereas at the time of sorting they did not express Gata2, Gata2 
expression could initiate after seeding Venus- HPCs in methylcellulose and cells thus 
undergo normal proliferation/differentiation. To test whether Venus- HPCs can convert to 
Venus+ cells, we analysed Venus expression in colonies derived from sorted YS fractions 
after 10 days of differentiation (Fig7). Venus expression was found in colonies derived from 
both fractions, indicating that a portion of Venus- cells start to express Gata2 during formation 
of a hematopoietic colony. Interestingly, colonies derived from Venus+ cells showed a Gr1+ 
and Mac1+ phenotype, whereas Venus- -derived colony cells were only Mac1+. This 
demonstrates that Gata2 is not necessary for a subset of HPCs and that Gata2 promotes 
more complex hematopoietic function in other progenitor subsets. 
  
Gata3/Gata4 redundancy in Gata2 independent progenitors 
The expression of Gata3 and Gata4 in Venus- AGM HPCs and aortic endothelial cells 
is intriguing and highlights the potential redundancy of Gata transcription factors in 
hematopoietic cell generation. Gata2 and Gata3 can partially rescue the erythroid phenotype 
in Gata1 deficient mice49,50 and while recently it was suggested that Gata3 is redundant in 
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HSCs51, others clearly show that it regulates HSC cell-cycle entry52 and self-renewal53. The 
fact that Gata3 and Gata4 are expressed in Gata2-non-expressing enriched HPCs suggests 
that they may function in this early progenitor subset. Gata3-deficient embryos show 
decreased numbers of FL HP/SCs54. Gata3 affects HSC development non-cell autonomously 
by activating the expression of Th (tyrosine hydroxylase) and hence, catecholamine 
production in the ventro-lateral cells of the sympathetic nervous system underlying the 
embryonic aorta36. HSC production was rescued when catecholamines were administered to 
the pregnant dams. These investigators also found that some aortic endothelial cells express 
a Gata3LacZ reporter, leaving open the possibility of a direct and overlapping role for Gata3 
in some HPCs.  
Much less is known concerning Gata4 in hematopoietic development. In Zebrafish 
there is a close relationship between anterior hemangioblasts and cardiac precursors55. 
Together with Gata5 and Gata6, Gata4 specifies these two anterior mesoderm derivatives. In 
mouse, Gata4 is a key component of the cardiac developmental program, with close 
associations between cardiac, vascular and hematopoietic lineages56-58. Moreover, a subset 
of mouse endocardial and YS endothelial cells express cardiac markers, possess hemogenic 
potential and give rise to transient definitive erythroid/myeloid progenitors59. Our results 
suggest the Gata4 aortic endothelial cells and Venus- Gata4-expressing HPCs may be 
derivatives of mesodermal cells with a genetic program that retains cardiac-vascular-
hematopoietic potential and can produce HPCs. Further examination of double reporter and 
deficient mice should reveal the overlapping and/or redundant roles of these Gata factors.  
 
Gata2 as a pivotal regulator of complex hematopoietic function.  
RNAsequence comparisons of the functionally distinct Venus+ and Venus- HPC 
subsets revealed a strong upregulation of Kras, and Ras pathway genes, in Venus+ HPCs. 
This pathway is particularly important in cell differentiation, acting as a molecular switch to 
relay extracellular growth signals60. Kras mutations confer a competitive-repopulating 
advantage to BM HSCs in transplantations and initiate leukemia in mice61. In human, Kras 
mutations (together with other cooperating gene mutations) are prevalent in patients with 
various forms of myelomonocytic and myeloid leukemia62. Interactions between oncogenic 
Ras and Gata2 have been proposed63. The normal function of Kras has not yet been 
explored fully. However, conditional deletion of Kras by Vav-Cre or Mx1-Cre does not affect 
HSCs or the adult hematopoietic system64. Yet chimeric mice, produced by Kras-/- ESC- 
blastocyst injection, show no contribution of Kras-/- cells to the hematopoietic system, 
suggesting that Kras may be important during the embryonic development of the 
hematopoietic system, but not after its generation.  
The low expression of Notch1, Notch4 and co-activators in the Venus- as compared to 
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the Venus+ HPC fraction, supports the fact that early hematopoietic cells are generated 
independent of this signaling pathway, or implies that these are differentiated cells which 
have turned off Notch signalling65. Others have shown that Notch1 deletion impairs the 
development of HSCs and angiogenesis66, but not YS primitive or definitive hematopoiesis. 
Moreover, Gata2 expression in the aortic endothelium is lost when Jagged1 (ligand) is 
deleted67. Our data demonstrate a direct relationship for Notch and Gata2 expression, 
strongly supporting a pivotal role for this pathway in the generation of functionally-complex 
hematopoietic cells. In the absence of Notch signaling, less complex HPC emerge in the 
AGM or are immigrants from the YS18,66,67. In addition, our observed upregulated-expression 
of some CREB genes in Venus+ HPCs supports the involvement of these regulators in 
definitive hematopoietic cell generation68. Our Gata2Venus model, in combination with 
recently reported Gata2 distal enhancer-Evi1 mouse model, will allow for a direct 
examination of the cells relevant to leukemogenesis12.    
In conclusion, we have enriched, localized and characterized Gata2-dependent and 
independent subsets of hematopoietic progenitors in Gata2Venus embryos. The combination 
of this reporter with other reporter and KO models will lead to a better understanding of the 
role of Gata2 (and other factors) in the development and function of multipotential HP/SCs in 
health, leukemogenesis and reprogramming.  
 
Acknowledgements 
We thank Prof Jim Palis for critical comments on this manuscript. Dr Dorota Kurek for 
providing anti-Gata3 and Gata4 antibodies; Drs Dorota Kurek and Mihaela Crisan for 
immunostaining support; Dr Siska Driegen for ESC culture support; Dr. Derk ten Berge for 
providing Wnt for ESC cultures. This work was supported by ZonMw (Dutch Medical 
Research Council 911-09-036), FES Netherlands Institute for Regenerative Medicine 
(101675), NIH (RO37 DK54077), ZonMW TOP (91211068), ERC Advanced Grant (341096) 
and LSBR (1344).  
 
Authorship Contributions 
PK, EdP, CE, MLK, MJ, CSV and TY performed research. PSK analysed RNAseq data. 
RvdL performed/analysed flow cytometric data. DM provided reagents. PK, EdP, CE, DM 
and ED designed experiments, analysed and interpreted data. PK, ED, EdP and CE wrote 
the manuscript.   
 
Disclosure of Conflicts of Interest 
The authors declare no conflicts of interest. 
  
13 
 
References  
1. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood 
stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell 
Stem Cell. 2010;7(4):532-544. 
2. Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, et al. Whole-transcriptome 
analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 
in HSC generation. J Exp Med. 2015;212(1):93-106. 
3. Swiers G, Baumann C, O'Rourke J, et al. Early dynamic fate changes in haemogenic 
endothelium characterized at the single-cell level. Nat Commun. 2013;4:2924. 
4. Fujiwara Y, Chang AN, Williams AM, Orkin SH. Functional overlap of GATA-1 and 
GATA-2 in primitive hematopoietic development. Blood. 2004;103(2):583-585. 
5. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the 
transcription factor GATA-2. Nature. 1994;371(6494):221-226. 
6. Tsai FY, Orkin SH. Transcription factor GATA-2 is required for proliferation/survival of 
early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal 
differentiation. Blood. 1997;89(10):3636-3643. 
7. de Pater E, Kaimakis P, Vink CS, et al. Gata2 is required for HSC generation and 
survival. J Exp Med. 2013;210(13):2843-2850. 
8. Ling KW, Ottersbach K, van Hamburg JP, et al. GATA-2 plays two functionally distinct 
roles during the ontogeny of hematopoietic stem cells. J Exp Med. 2004;200(7):871-882. 
9. Rodrigues NP, Janzen V, Forkert R, et al. Haploinsufficiency of GATA-2 perturbs 
adult hematopoietic stem-cell homeostasis. Blood. 2005;106(2):477-484. 
10. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by 
mutations in a conserved intronic element leads to MonoMAC syndrome. Blood. 
2013;121(19):3830-3837, S3831-3837. 
11. Groschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer 
rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 
2014;157(2):369-381. 
12. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer 
drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 
2014;25(4):415-427. 
13. Heyworth C, Gale K, Dexter M, May G, Enver T. A GATA-2/estrogen receptor 
chimera functions as a ligand-dependent negative regulator of self-renewal. Genes Dev. 
1999;13(14):1847-1860. 
14. Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 
transcription factor blocks normal hematopoiesis. Blood. 1999;93(2):488-499. 
14 
 
15. Nandakumar SK, Johnson K, Throm SL, Pestina TI, Neale G, Persons DA. Low-level 
GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid 
differentiation in mice. Exp Hematol. 2015;43(7):565-577 e510. 
16. Minegishi N, Suzuki N, Yokomizo T, et al. Expression and domain-specific function of 
GATA-2 during differentiation of the hematopoietic precursor cells in midgestation mouse 
embryos. Blood. 2003;102(3):896-905. 
17. Ottersbach K, Dzierzak E. Analysis of the mouse placenta as a hematopoietic stem 
cell niche. Methods Mol Biol. 2009;538:335-346. 
18. Robert-Moreno A, Espinosa L, de la Pompa JL, Bigas A. RBPjkappa-dependent 
Notch function regulates Gata2 and is essential for the formation of intra-embryonic 
hematopoietic cells. Development. 2005;132(5):1117-1126. 
19. Gao X, Johnson KD, Chang YI, et al. Gata2 cis-element is required for hematopoietic 
stem cell generation in the mammalian embryo. J Exp Med. 2013;210(13):2833-2842. 
20. Lim KC, Hosoya T, Brandt W, et al. Conditional Gata2 inactivation results in HSC loss 
and lymphatic mispatterning. J Clin Invest. 2012;122(10):3705-3717. 
21. Orlic D, Anderson S, Biesecker LG, Sorrentino BP, Bodine DM. Pluripotent 
hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-
myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-
stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci U S A. 1995;92(10):4601-
4605. 
22. Sakai K, Miyazaki J. A transgenic mouse line that retains Cre recombinase activity in 
mature oocytes irrespective of the cre transgene transmission. Biochem Biophys Res 
Commun. 1997;237(2):318-324. 
23. Yokomizo T, Yamada-Inagawa T, Yzaguirre AD, Chen MJ, Speck NA, Dzierzak E. 
Whole-mount three-dimensional imaging of internally localized immunostained cells within 
mouse embryos. Nat Protoc. 2012;7(3):421-431. 
24. Medvinsky A, Taoudi S, Mendes S, Dzierzak E. Analysis and manipulation of 
hematopoietic progenitor and stem cells from murine embryonic tissues. Curr Protoc Stem 
Cell Biol. 2008;Chapter 2:Unit 2A 6. 
25. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential 
analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 
2013;31(1):46-53. 
26. Mootha VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein 
composition, tissue diversity, and gene regulation in mouse mitochondria. Cell. 
2003;115(5):629-640. 
15 
 
27. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad 
Sci U S A. 2005;102(43):15545-15550. 
28. Johnson KD, Hsu AP, Ryu MJ, et al. Cis-element mutated in GATA2-dependent 
immunodeficiency governs hematopoiesis and vascular integrity. J Clin Invest. 
2012;122(10):3692-3704. 
29. Nardelli J, Thiesson D, Fujiwara Y, Tsai FY, Orkin SH. Expression and genetic 
interaction of transcription factors GATA-2 and GATA-3 during development of the mouse 
central nervous system. Dev Biol. 1999;210(2):305-321. 
30. Pimanda JE, Ottersbach K, Knezevic K, et al. Gata2, Fli1, and Scl form a recursively 
wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U 
S A. 2007;104(45):17692-17697. 
31. Yokomizo T, Dzierzak E. Three-dimensional cartography of hematopoietic clusters in 
the vasculature of whole mouse embryos. Development. 2010;137(21):3651-3661. 
32. Impey S, McCorkle SR, Cha-Molstad H, et al. Defining the CREB regulon: a genome-
wide analysis of transcription factor regulatory regions. Cell. 2004;119(7):1041-1054. 
33. Zhang X, Odom DT, Koo SH, et al. Genome-wide analysis of cAMP-response 
element binding protein occupancy, phosphorylation, and target gene activation in human 
tissues. Proc Natl Acad Sci U S A. 2005;102(12):4459-4464. 
34. McGrath KE, Frame JM, Fegan KH, et al. Distinct Sources of Hematopoietic 
Progenitors Emerge before HSCs and Provide Functional Blood Cells in the Mammalian 
Embryo. Cell Rep. 2015;11(12):1892-1904. 
35. Kierdorf K, Erny D, Goldmann T, et al. Microglia emerge from erythromyeloid 
precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16(3):273-280. 
36. Fitch SR, Kimber GM, Wilson NK, et al. Signaling from the sympathetic nervous 
system regulates hematopoietic stem cell emergence during embryogenesis. Cell Stem Cell. 
2012;11(4):554-566. 
37. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. Dynamic regulation of PU.1 expression 
in multipotent hematopoietic progenitors. J Exp Med. 2005;201(2):221-231. 
38. Khandekar M, Brandt W, Zhou Y, et al. A Gata2 intronic enhancer confers its pan-
endothelia-specific regulation. Development. 2007;134(9):1703-1712. 
39. Butko E, Distel M, Pouget C, et al. Gata2b is a restricted early regulator of hemogenic 
endothelium in the zebrafish embryo. Development. 2015;142(6):1050-1061. 
40. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult 
microglia derive from primitive macrophages. Science. 2010;330(6005):841-845. 
16 
 
41. Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages 
originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518(7540):547-
551. 
42. Herbomel P, Thisse B, Thisse C. Zebrafish early macrophages colonize cephalic 
mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-
dependent invasive process. Dev Biol. 2001;238(2):274-288. 
43. Ditadi A, Sturgeon CM, Tober J, et al. Human definitive haemogenic endothelium and 
arterial vascular endothelium represent distinct lineages. Nat Cell Biol. 2015;17(5):580-591. 
44. Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. 
Exp Hematol. 2001;29(8):927-936. 
45. Frame JM, McGrath KE, Palis J. Erythro-myeloid progenitors: "definitive" 
hematopoiesis in the conceptus prior to the emergence of hematopoietic stem cells. Blood 
Cells Mol Dis. 2013;51(4):220-225. 
46. Lux CT, Yoshimoto M, McGrath K, Conway SJ, Palis J, Yoder MC. All primitive and 
definitive hematopoietic progenitor cells emerging before E10 in the mouse embryo are 
products of the yolk sac. Blood. 2008;111(7):3435-3438. 
47. Rhodes KE, Gekas C, Wang Y, et al. The emergence of hematopoietic stem cells is 
initiated in the placental vasculature in the absence of circulation. Cell Stem Cell. 
2008;2(3):252-263. 
48. Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, de Bruijn M. From 
hemangioblast to hematopoietic stem cell: an endothelial connection? Exp Hematol. 
2005;33(9):1029-1040. 
49. Takahashi S, Shimizu R, Suwabe N, et al. GATA factor transgenes under GATA-1 
locus control rescue germline GATA-1 mutant deficiencies. Blood. 2000;96(3):910-916. 
50. Tsai FY, Browne CP, Orkin SH. Knock-in mutation of transcription factor GATA-3 into 
the GATA-1 locus: partial rescue of GATA-1 loss of function in erythroid cells. Dev Biol. 
1998;196(2):218-227. 
51. Buza-Vidas N, Duarte S, Luc S, Bouriez-Jones T, Woll PS, Jacobsen SE. GATA3 is 
redundant for maintenance and self-renewal of hematopoietic stem cells. Blood. 
2011;118(5):1291-1293. 
52. Ku CJ, Hosoya T, Maillard I, Engel JD. GATA-3 regulates hematopoietic stem cell 
maintenance and cell-cycle entry. Blood. 2012;119(10):2242-2251. 
53. Frelin C, Herrington R, Janmohamed S, et al. GATA-3 regulates the self-renewal of 
long-term hematopoietic stem cells. Nat Immunol. 2013;14(10):1037-1044. 
54. Pandolfi PP, Roth ME, Karis A, et al. Targeted disruption of the GATA3 gene causes 
severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet. 
1995;11(1):40-44. 
17 
 
55. Peterkin T, Gibson A, Patient R. Common genetic control of haemangioblast and 
cardiac development in zebrafish. Development. 2009;136(9):1465-1474. 
56. Fehling HJ, Lacaud G, Kubo A, et al. Tracking mesoderm induction and its 
specification to the hemangioblast during embryonic stem cell differentiation. Development. 
2003;130(17):4217-4227. 
57. Huber TL, Kouskoff V, Fehling HJ, Palis J, Keller G. Haemangioblast commitment is 
initiated in the primitive streak of the mouse embryo. Nature. 2004;432(7017):625-630. 
58. Van Handel B, Montel-Hagen A, Sasidharan R, et al. Scl represses cardiomyogenesis 
in prospective hemogenic endothelium and endocardium. Cell. 2012;150(3):590-605. 
59. Nakano H, Liu X, Arshi A, et al. Haemogenic endocardium contributes to transient 
definitive haematopoiesis. Nat Commun. 2013;4:1564. 
60. Pierre S, Bats AS, Chevallier A, et al. Induction of the Ras activator Son of Sevenless 
1 by environmental pollutants mediates their effects on cellular proliferation. Biochem 
Pharmacol. 2011;81(2):304-313. 
61. Sabnis AJ, Cheung LS, Dail M, et al. Oncogenic Kras initiates leukemia in 
hematopoietic stem cells. PLoS Biol. 2009;7(3):e59. 
62. Chang YI, You X, Kong G, et al. Loss of Dnmt3a and endogenous Kras cooperate to 
regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia. 
2015. 
63. Katsumura KR, Yang C, Boyer ME, Li L, Bresnick EH. Molecular basis of crosstalk 
between oncogenic Ras and the master regulator of hematopoiesis GATA-2. EMBO Rep. 
2014;15(9):938-947. 
64. Kong G, Liu Y, Chang Y-I, Zhang J, Chang Q, Zhang J. Kras Plays An Important Role 
In Generating Differentiated Blood Cells. Vol. 122; 2013. 
65. Richard C, Drevon C, Canto PY, et al. Endothelio-mesenchymal interaction controls 
runx1 expression and modulates the notch pathway to initiate aortic hematopoiesis. Dev Cell. 
2013;24(6):600-611. 
66. Kumano K, Chiba S, Kunisato A, et al. Notch1 but not Notch2 is essential for 
generating hematopoietic stem cells from endothelial cells. Immunity. 2003;18(5):699-711. 
67. Robert-Moreno A, Guiu J, Ruiz-Herguido C, et al. Impaired embryonic 
haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1. 
EMBO J. 2008;27(13):1886-1895. 
68. Kim PG, Nakano H, Das PP, et al. Flow-induced protein kinase A-CREB pathway 
acts via BMP signaling to promote HSC emergence. J Exp Med. 2015;212(5):633-648. 
 
  
18 
 
 
Table 1. Frequency of Venus+ cells in embryonic tissues of G2V embryos. 
 
 
 
 
 
 
 
 
 
 
 
The frequency of Venus positive cells within the viable cell fraction of embryonic tissues per embryo is 
presented. FACS analysis of single cell suspensions of dissected embryonic tissues (YS, yolk sac; PL, 
placenta; AGM, aorta-gonads-mesonephros; FL, fetal liver) was performed to define the percentage of 
cells expressing Venus. AGM contains part of the vitelline and umbilical arteries. Our data for the total 
number of cells in each tissue (data not shown) correlated with published data for YS and E9.5 AGM 
(Dzierzak and de Bruijn 2002) and for FL (Gekas, Dieterlen-Lievre et al. 2005). The data represents the 
mean ± SEM of 3-6 independent experiments with exception of E11 YS and PL data (data represents 
the mean ± STD of 1 experiment. (n=number of independent experiments, number of individual embryos 
analysed), E=embryonic day, sp=somite pairs; nd=not done. 
 
 
 
 
  
Tissue Stage  (number of experiments, embryos analyzed) 
% Venus+ 
cells/tissue 
AGM E9, 16-25sp (n=4, 22) 1.82 ± 0.31 
 E10, 28-36sp (n=4, 29) 3.27 ± 0.52  
 E11, 43-49sp (n=4, 25) 7.86 ± 1.1  
FL E9 nd nd 
 E10, 28-36sp (n=4, 10) 13.89 ± 0.7 
 E11, 43-49sp (n=4, 19) 19.27 ± 2.14 
YS E9, 16-25sp (n=5, 8) 6.28 ± 0.47 
 E10, 28-36sp (n=6, 9) 6.17 ± 0.86 
 E11, 42-46sp (n=1, 3) 5.25 ± 0.59 
PL E9, 17-23sp (n=3, 4) 10.91 ± 0.49 
 E10, 28-35sp (n=3, 6) 10.8 ± 1.92 
 E11, 42-46sp (n=1, 3) 15.01 ± 4.64 
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Table 2. CFU-C number in Venus+ and Venus- cell fractions of G2V embryonic tissues  
 
Tissue Stage 
(number of 
experiments, 
embryos 
analyzed) 
CFU-C/tissue/sorted cell fraction 
   Venus- Venus+ 
AGM  E9, 20-23sp (n=2, 5) 0.4 ± 0.4 8.0 ± 2.1  
 E10, 32-35sp (n=2, 6) 8.0 ± 2.3 69.0 ± 7.1  
VA+UA E9, 20-23sp (n=2, 5) 0.8 ± 0.5 2.4 ± 1.0  
 E10, 32-35sp (n=2, 6) 7.0 ± 1.5 197.7 ± 36.9  
YS  E9, 20-23sp (n=2, 5) 270.0 ± 69.8 1020 ± 137.3 
 E10, 32-35sp (n=2, 5) 130.0 ± 25.5 1252.0 ± 156.0  
PL E9, 20-23sp (n=2, 5) 4.0 ± 1.3 22.0 ± 2.5  
 E10, 32-35sp (n=2, 6) 14.5 ± 5.3 251.7 ± 32.4  
FL  E10, 32-35sp (n=2, 6) 20.5 ± 7.6 248.7 ± 75.2  
     
 
Number of total CFU-C (mean ± SEM) per tissue per G2V embryo for the sorted Venus- and Venus+ 
cell fractions at E9 and E10. E=embryonic day, sp=somite pair. (n=number of independent 
experiments, number of individual embryos analysed). 
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Table 3. CFU-C number per E9-E10 Gata2-deleted hematopoietic tissues. 
 
 
 
Number of total CFU-C (mean ± SEM) per tissue shown for WT, Gata2 germline and conditional 
knockout embryos at E9 and E10. WT=wild type, E=embryonic day, sp=somite pair, (n=number of 
independent experiments, number of individual embryos analysed), *p < 0.05; **p < 0.01 
 
 
 
 
 
 
 
  
Tissue Stage Genotype 
  WT Gata2+/- Gata2-/- 
AGM E9, 20-23sp 8.5 ± 2.3 (n=1, 4) 2.25 ± 0.9* (n=1, 4) 3.0 ± 1.0  (n=1, 2) 
 E10, 28-34sp 62.4 ± 20.8 (n=3, 7) 24.0 ± 7.4* (n=3, 13) 16.7 ± 6.8* (n=3, 9) 
VA+UA E9, 20-23sp 7.0 ± 0.6 (n=1, 4) 2.25 ± 0.6* (n=1, 4) 5.0 ± 2.0  (n=1, 2) 
 E10, 28-34sp 241.1 ± 67.8 (n=3, 7) 78.7 ± 12.3** (n=3, 13) 12.0 ± 2.5** (n=3, 9) 
YS E9, 20-23sp 772.5 ± 85.3 (n=1, 4) 500.0 ± 71.5* (n=1, 4) 64.4 ± 12.2** (n=1, 2) 
 E10, 28-34sp 918.6 ± 147.9 (n=3, 7) 584.6 ± 89.0** (n=3, 9) 25.7 ± 8.0** (n=2, 3) 
  Gata2f/+ or Gata2f/f VEC-Cre:Gata2f/+ VEC-Cre:Gata2-/- 
FL E10, 30-34sp 115.8 ± 35.0 (n=2, 5) 83.0 ± 20.8 (n=2, 6) 22.2 ± 6.7* (n=2, 6) 
PL E10, 30-34sp 406.0 ± 134.0 (n=2, 5) 81.0 ± 25.0* (n=2, 6) 12.0 ± 4.0* (n=2, 6) 
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Figure Legends 
 
Figure 1. Gata2 Venus reporter construction and validation. (A) Schematic diagram of 
the IRES Venus reporter-selection cassette insertion in the 3’UTR of the mouse Gata2 locus 
and Cre-mediated removal of lox PGK-Puro lox. Primers used for detection of the targeted 
and recombined alleles are indicated flanking the loxP sites (yellow). (B) Representative flow 
cytometric analysis and sorting plot of Venus-expressing cells in the bone marrow (BM) of 
adult Gata2 Venus (G2V) mice. Gated regions show percentage positive and negative viable 
cells. (C) Relative levels of Gata2 and Venus mRNA in sorted Venus+ and Venus- Gata2V/+ 
cells BM cells as determined by qRT-PCR. Gata2 transcripts in Venus+ 
cells=0.11337±0.00681 and Venus- cells=0.00012±0.00003, p=0.000076. Venus transcripts 
in Venus+ cells=0.06722±0.00799 and Venus- cells=0.00036±0.00010, p=0.00112. mean ± 
SEM, n=3. (D) Competitive limiting dilution transplantation strategy used to test the quantity 
and robustness of Gata2V/V BM HSCs as compared to wild type. Percentage of donor cell 
chimerism in adult irradiated recipients co-transplanted with the same number of wild type 
(WT) Ly5.1/5.2 and Gata2 Venus (G2V/V) Ly5.2 bone marrow cells. Varying numbers (1x105, 
3x105, 3x106) of bone marrow cells of each genotype were injected and peripheral blood of 
recipients was analysed for donor cell engraftment by FACS at 1 and 4 months post 
transplantation. n=2 (5 mice per group). (E) Representative FACS plots demonstrating 
frequency of Venus expressing cells in E11 AGM, YS, PL and FL. Gates indicate Venus- and 
Venus+ cell fractions. Percentages represent the frequency of Venus+ cells within the viable 
cell fraction (See Table 1).   
 
Figure 2. Localization of Gata2Venus expressing cells in embryonic hematopoietic 
sites. Confocal images of a whole mount immunostained E10.5 Gata2Venus embryo 
showing (A) Venus; green, (B) CD31; magenta and (C) merged expression. Venus 
expressing cells are detected in the aorta-gonad-mesonephros (AGM) along the wall of the 
dorsal aorta (dotted lines), the fetal liver (FL), neural tube (NT) and olfactory bulb (OB). (D) 
Confocal image of a transverse section through the E10.5 AGM. DAPI staining (blue), CD31 
(red) and Venus fluorescence (green) reveal Gata2-expressing aortic endothelial and 
hematopoietic cluster cells, urogenital (UG) and liver (FL) cells. Enlarged images of panel D 
showing Gata2-expressing cells in (E) AGM (DA=dorsal aorta; UG=uro-genital ridges; 
arrowheads indicate hematopoietic cluster) and (F) FL. Venus (green) and CD34 (red) 
fluorescence showing endothelial and hematopoietic cluster cells in (G) E9 paired aorta (H) 
umbilical artery (UA) at E9 and (I) E11 aorta. Arrowheads indicate hematopoietic cluster. (J-
M) Images of E10.5 yolk sac (YS) section showing DAPI merged, Venus, CD31 and merged 
fluorescence. Arrow denotes an endothelial cell expressing Venus and CD31.  
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Figure 3. Quantitation of functional HSCs and HPCs in G2V embryonic hematopoietic 
tissues. HSCs in sorted Venus+ and Venus- cell fractions of E11 AGM were analysed by 
transplantation into irradiate adult recipients. (A) Percentage donor cell chimerism was 
determined by Venus PCR of peripheral blood DNA at 4 months post-transplantation. Each 
dot represents one recipient receiving 1.7-6.5 ee of AGM cells. n=7. **p=0.0089. (B-G) 
Hematopoietic progenitor number per tissue in sorted Venus+ and Venus- cell fractions of (B) 
E9 and E10 AGM, (C) E9 and E10 VA+UA, (D) E9 and E10 yolk sac (YS), E9 and E10 
placenta (PL), and (F) E10 fetal liver (FL). Colony forming unit–culture (CFU-C) per one ee of 
tissue is shown. Colony types designated by colored bars are CFU-granulocyte, erythroid, 
macrophage, megakaryocyte (GEMM); CFU-granulocyte, macrophage (GM); CFU-
macrophage (M); CFU-granulocyte (G) and Burst forming unit-erythroid (BFU-E). SEM of 
total CFU-C is shown. 2 ee of somite pair matched tissues were pooled for sorting and 
yielded 1ee for colony analysis.  
 
Figure 4. CFU-C numbers and vascular hematopoietic clusters in Gata2-/- embryos. 
CFU-C numbers per embryo equivalent (ee) found in (A) E9 and E10 AGM, (B) E9 and E10 
VA+UA, (C) E9 and E10 YS, (D) E10 placenta. *p<0.05; **p<0.01. (E) Quantitation of cKit+ 
hematopoietic cluster cells in VA+UA of E10 Gata2+/+, Gata2+/- and Gata2-/- embryos. (F) 
Representative whole mount images of hematopoietic cluster cells in the VA of E10 Gata2+/+ 
(30 sp), Gata2+/- (31 sp) and Gata2-/- (30 sp) embryos stained for cKit expression.  
Figure 5. Differential expression of signalling pathway modulators in Gata2 dependent and 
independent HPCs. (A) Flow cytometric sorting gates for isolation of E10.5 AGM G2V 
CD31+cKitintVenus- (grey) and CD31+cKitintVenus- (green) HPCs used for RNA sequence 
analysis. GEO Data Accession Number is GSE76254. (B) Gene enrichment analysis for Ras 
signaling pathway genes. Bar graphs of FPKM values obtained from RNA sequence analysis 
of CD31+cKitintVenus- (grey bar) and CD31+cKitintVenus+ (green bar) AGM cells for (C) Ras 
pathway and CREB and CBP transcription factor genes and (D) Notch pathway genes. (E) 
Bar graphs of FPKM values obtained from RNA sequence analysis for a selection of 
chemokine receptor/ligand genes (see Kiedorf et al, 2013; these genes were down-
/upregulated in YS EMPs as compared to adult microglia (AM)). (F) Representative FACS 
plots demonstrating frequency of EMPs in the Venus+ fraction, as defined as Sca1-
ckit+CD41+CD16/32+, in YS and AGM of E10 (left) and E11 (right) G2V embryos. Numbers 
indicate the percentages of gated cells within the parental cell population.  
 
Figure 6. Gata family gene expression in AGM Gata2 dependent and independent 
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HPCs. (A) qRT-PCR for expression of Gata1, 2, 3, 4, 5 and 6 transcription factors 
(normalization with Gapdh) in E11 AGM CD31+cKit+Venus+ and CD31+cKit+Venus- cells. n=3. 
SEM shown with *p=0.05 and ***p=0.001 (B) Transverse section of WT E10.5 AGM 
immunostained for CD34 (magenta) and Gata3 (green) showing expression of Gata3 in the 
aortic endothelial cells and some emerging hematopoietic cells and ventral mesenchymal 
cells directly under the aorta. (C) Transverse section of G2V E10.5 AGM immunostained for 
CD34 (magenta), Gata2 (green) and Gata3 (red) showing some overlapping expression of 
Gata2 and Gata3 in aortic endothelial cells (arrowheads). (D) Transverse consecutive 
sections of E11 G2V AGM immunostained for CD34 (magenta) and Venus (green) in the top 
panels and for CD34 (magenta) and Gata4 (red) in the bottom panels. Gata4 expression is 
observed in some ventral aortic endothelial cells and emerging hematopoietic cells (arrow). 
 
Figure 7. Gata2 is expressed by Venus- cells after culture. Schematic diagram showing 
method and FACS analysis by which Gata2 expression was found in the progeny of sorted 
Venus- HPCs. G2V YS tissue was FACS sorted into Venus- and Venus+ fractions. Cells were 
subsequently seeded in methylcellulose and colonies analysed after 10 days of culture. 
Colonies were harvested from the dish and cells are washed, stained (with anti-Gr1 and anit-
Mac1 antibodies) and Venus, Gr1 and Mac1 expression was analysed by FACS. FACS plots 
(top) indicate Venus expression in cells harvested from Venus- (left) and Venus+ (right) CFU-
C experiments. Note that both FACS analyses indicate Venus expression in both cultures. 
FACS plots (bottom) show Gr1 and Mac1 expression in Venus- and Venus+ populations in 
both cultures, and that cells harvested from Venus+ culture show a more immature 
phenotype.  
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Online Supplemental Methods 
Gata2Venus ESC and mice. Gata2 homology arms were amplified with primers as specified 
in Supplemental Table 1 and cloned into TOPO (Invitrogen). An IRES-Venus fragment was 
inserted between left and middle, and loxP-PGK-Puro-loxP between middle and right arms in 
pSP72. IB10 ESCs were transfected with linearized vector (20µg), puromycin-selected and 
360 clones PCR screened for Gata2 Venus (right arm junction – primers in Table1; 2292bp). 
Correct integration was verified by Southern blot (left arm) for 2 clones with normal 
karyotype. ESC+MEF were cultured in DMEM, 15%FBS, 1%Glutamax, 1%non-essential 
amino acids, 1%sodium pyruvate, 50µM βmercaptoethanol, 1000U/ml LIF at 37oC, 5%CO2. 
Founders were identified by Venus PCR. First generation G2V offspring were crossed with 
CAG-Cre mice 22 and backcrossed (>10 generations) with C57BL/6. 
 
Mice and embryo production.  Gata2+/-mice 5, Ly5.1 (6-8 week) and C57BL/6 mice were 
obtained/maintained (Harlan or locally) and genotyped by PCR. For PCR primers see 
Supplemental Table1. Day of plug discovery is embryonic day (E)0. Embryos were 
individually staged by somite pair (sp): E9=16-28sp, E10=28-40sp, early E10=28-34sp, 
E10.5=35-40sp, E11=40-50sp. 
 
Immunostaining. Whole-mount conceptuses 23 were suspended in PBS/10%FCS, fixed in 
2%PFA, and 100%MeOH. The trunk was dissected, anti-cKit and anti-CD31 stained, made 
transparent in 1:2BABB, and analysed (LeicaSP5) with Z-stack reconstructions (50–150µm) 
by LasAFsoftware. For cryosectioning 8 embryos were fixed in 2%PFA (20min), suspended in 
20%sucrose O/N, snap-frozen in TissueTec, sectioned (HM630 cryostat) and fixed 
(acetone). Anti-CD34-biotin (1:50, BD), anti-Gata3 (1:10 clone KT122, 111207H09, Absea) 
and anti-Gata4 (1:50, sc-9053, SantaCruz) and anti-GFP antibodies O/N and secondary 
antibody incubation at RT, DAPI counterstained, mounted (Vectashield) and imaged 
(LeicaSP5). For flow cytometry, cell suspensions were made by collagenase treatment or 
direct dissociation and filtration 8, stained with anti-CD31 (390, BD), anti-CD34 (RAM34, BD), 
anti-cKit (2B8, BD), anti-CD41 (MWReg3, SantaCruz), anti-Sca1 (D7, Ebiosciences) and 
anti-CD16/32 (2.4G2, BD) antibodies, Hoechst 33258 (BD) and analysed on a 
FACSARIAIII/SORP.  
 
Hematopoietic assays. Venus-sorted E9, E10, E11AGM, V+U, PL and YS and E10FL or 
Gata2-deficient E9-E10 AGM, V+U and PL (1 embryo equivalent (ee) of E9, E10 and E11 
AGM, 0.1 ee V+U V+, 0.1 ee PL V+,0.1 ee YS V-, 0.03 ee YS V+ and 0.1 ee E10 FLs) were 
seeded in 3.6ml Methylcellulose (1ml per dish; M3434, StemCellTech)(or 0.9 and 0.1 ee of 
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Gata2-/- V+U and Gata2-/- YS 0.1 and 0.03 ee were seeded in 1.2 ml and distributed in a 
single dish) and cultured for 10-12 days24. Colonies were isolated, washed and Venus 
expression examined by FACSARIAIII/Fortessa. Sorted G2V E11AGM (Ly5.1/Ly5.2) cells 
were transplanted as described previously24. In short, AGMs were dissected and collagen II 
treated for 45 minutes. Subsequently dissociated and washed. When appropriate, the cells 
were stained and subsequently FACS sorted and collected in 50% FCS/ 50% PBS. Sorted 
G2V E11 AGM (Ly5.1/Ly5.2) cells were washed to PBS and injected into 9.5 Gy-irradiated 
(C57BL/6 x 129)F1 recipients (Ly5.2/Ly5.2) together with 2x105 spleen cells from the 
recipient strain. Peripheral blood (PB) donor chimerism was determined by Venus PCR or 
FACS at 1 and 4mo post-transplantation and scored positive if PB donor chimerism was 
>10% and multiorgan/lineage chimerism was >1%. For secondary transplantations, 3x106 BM 
cells from primary reconstituted recipients (4mo post-transplantation) were injected into 9.5 
Gy-irradiated recipients and repopulation analysed at 4mo post-transplantation.  
 
RNA analyses.  E10.5 AGM cells were stained and sorted (CD31-PE-Cy7, 390, Biolegend; 
ckit-APC, 288, BD), washed, resuspended in RNAlater (LifeTechnologies) and stored at 
−20°C. RNA preparation was with mirVana miRNA Kit (Ambion) and quality/quantity were 
assessed on a 2100 bioanalyzer (Agilent Technologies) with a RNA Nano/Pico chip. 
RNAsequencing used SMARTER protocol for Illumina HiSeq2000. Sequences were mapped 
to mouse (version 10) and FPKMs calculated using TopHat (v2.0.13) and Cufflinks (v2.2.1) 
with fragment-bias and multi-read corrections25. Expression difference threshold was >2-fold 
change and higher or lower expressing genes were applied to Enrichr tool. Enrichr output 
(and calculated p-values from Chi2 tests) were imported into R and corrected for multiple 
testing (FDR) and a threshold of FDR <0.05 was used. For GSEA, ratios were calculated for 
AGM CD31+c Kit+Venus- versus CD31+cKit+Venus+ FPKMs(+1) and used with GSEA 
(version2.2.0) preranked method using default options26,27. GEO Data Accession Number is 
GSE76254. 
For qRT-PCR, SuperScriptII or III ReverseTranscriptase (LifeTechnologies) was used 
for first-strand cDNA synthesis. Reaction mix=0.2µM forward (F) and reverse (R) primers, 2µl 
cDNA, 0.2mM nucleotides and 1U Platinum®Taq Polymerase (LifeTechnologies) with 30-40 
cycles (Bio-Rad rtPCRThermocycler): with primers as described in supplementary table 1. β-
actin was used for normalization.  
 
 
 
  
33 
 
Supplemental Table 1. Primer sequences 
 
Cloning Fwd Rev 
left 5’AATCGATGCCGAGGGAGTTCAGTGCTAG3’ 5’AGATATCACAGTAATGGCGGCACAAGGC3’ 
right 5’ATACGTACAGGAAGGAAACATTCTCTGG3 5’ACTCGAGGTCTCAGGCAAGACTATGG3’ 
middle 5’CATATGGCCTGGAATCTGCGCAGGAC3’ 5’GCGGCCGCAATATTTCTAACTGGGCTGC3’ 
Genotyping    
right arm 
junction 5’CAGCTTCAGCCTGCTTACTCA3’ 5’TATAGACAAACGCACACCGGC3’ 
Gata2-/- GGAACGCCAACGGGGAC GCTGGACATCTTCCGATTCCGGGT 
qRT-PCR  GATCTCCTGTCATCTCACCTTGCT 
Venus F5’ATCTTCTTCAAGGACGACGG3’ R5’GGCTGTTGTAGTTGTACTCC3’ 
Gata2 F5’ AAGCTGCACAATGTTAACAGG3’ R5’CCTTTCTTGCTCTTCTTGGAC3’ 
Gata1 F5’TGCCTGTGGCTTGTATCA3’ R5’TGTTGTAG GGTCGTTTGAC3’ 
Gata3 F5’CCTTATCAAGCCCAAGCGA3’ R5’GATGCCTTCTTTCTTCATAGTCAG3’ 
Gata4 F5’GAGCTGGTGCTACCAAGAGG3’ F5’GAGCTGGTGCTACCAAGAGG3’ 
Gata5 F5’CGACGTAGCCCCTTCGTGG3’ R5’GCCACAGTGGTGTAGACAG3’ 
Gata6 F5’GCCTGCGGCCTCTACATGAA3’ R5’CAGGACCTGCTGGCGTCTTA3’ 
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Supplemental Figure 1  
Representative multilineage FACS analysis of GataVenus+ repopulated recipients. 
Recipients repopulated with Venus+ cells from G2V E11 AGM were examined at 4mo post-
transplantation for donor-derived cells. Bone marrow (BM), spleen, lymph node (LN), 
peripheral blood (PB) and thymus cells were isolated and examined for the Ly5.1 donor 
marker in multiple lineages. (Top panel) BM viable cells were gated into the following 
fractions - CD31+Gr- =lymphoid; CD31-Gr1- =erythroid; CD31+Gr1+ and CD31-Gr1+ =myeloid. 
(Second row panels) percentages of Ly5.1 (Y-axis) cells in gated erythroid, lymphoid and 
myeloid lineage fractions are indicated. (Third row, Left panel) Spleen viable cells were gated 
on B cells (B220+) and T cells (CD4+/CD8+) and (Right panels) show percentages of Ly5.1 
(Y-axis) donor-derived B and T cells. (Bottom row panels) Percentages of Ly5.1 donor-
derived cells are shown for viable cells from LN, PB and Thymus. X-axis is side scatter 
(SSC-A) in all Ly5.1 plots.       
 
 
